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Abstract
Bleomycin is known to cause double strand breaks in vitro. Little is known,
however, about its mechanism of genotoxicity in vivo. One way to probe the mechanism
of genotoxicity of a DNA damaging agent in vivo is to compare the relative sensitivities
of a wild type Escherichia coli strain to a panel of isogenic repair deficient mutants. If
the pathway defective in the mutant is known (e.g., base excision repair, alkyltransferase
repair, nucleotide excision repair, and so on), the sensitivity of the mutant can reveal
mechanistic insight into the mode of killing by the DNA damaging agent. In this study,
mutants deficient in recombinational repair, specifically recF, recBCD, ruvABC, recG
and recGruvC, were examined for sensitivity to bleomycin. This sensitivity was tested in
both dividing and non-dividing cells in order to analyze the effect of cell division on the
cytotoxicity of bleomycin.
When non-dividing cells were treated, the recBCD and recGruvC mutants,
demonstrated high sensitivity to bleomycin. The recF mutant, on the other hand,
demonstrated no sensitivity. These results were consistent with the conclusion that
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bleomycin induces double strand breaks in vivo that are repaired by the recombinational
repair double strand break pathway. It also suggests that no damage was induced by
bleomycin that required repair by the daughter strand gap pathway.
Examining the sensitivity of recombinational repair deficient mutants to
bleomycin also gave new insights about the mechanism of recombinational repair. Both
ruvABC and recG gene products resolve Holliday junctions; however, they are thought to
work on separate recombinational pathways. In this study, although the recGruvC strain
was highly sensitive to bleomycin, the ruvABC and the individual recG and ruvC strains
were not. This result suggested redundancy in the functions of the RecG and RuvABC
proteins.
Dividing cells showed a marked increase in sensitivity to bleomycin as compared
to non-dividing cells. In addition, the functional redundancy of recG and ruvABC
mutants was no longer seen. The ruvABC strain demonstrated high sensitivity equal to
that of the recGruvC and recBCD strains whereas the recG and ruvC strains were only
slightly sensitive. Under these conditions of increased cytotoxicity, additional functions
of the RuvAB enzymes became important for suppression of toxicity. This result
suggested a change in the mechanism of bleomycin's genotoxicity.
Thesis Supervisor: John Essigmann
Title: Professor of Chemistry and Toxicology
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Chapter I Introduction and Background
PART A: RESEARCH OBJECTIVES
Bleomycin is a glycopeptide antibiotic isolated from Streptomyces verticilles (1).
Its ability to kill dividing cells specifically has made this drug important in the treatment
of a variety of cancers, including testicular carcinoma, Hodgkin's disease and squamous
cell carcinoma of the head and neck (2; 3). Although bleomycin has been used clinically
for many years, the exact mechanism of its cytotoxicity, which is believed to be linked
with DNA damage, is still poorly understood.
Many studies have focused on the interaction of bleomycin with DNA. They have
shown that bleomycin can induce various DNA lesions in vitro, namely abasic sites,
single strand breaks, and double strand breaks. Little has been done, however, to
examine if these damages occur in vivo. The primary objective of the present study was
to test whether the genotoxicity of bleomycin in vivo is due to its ability to induce double
strand breaks.
The experimental procedure used to achieve the aforementioned goal was to
compare the relative sensitivities of wild type Escherichia coli cells and a panel of
mutants to bleomycin. The mutants studied were lacking proteins involved in
recombinational processing of DNA damage. The results of this analysis revealed
mechanistic insight into the genotoxicity of bleomycin. Moreover, beyond the particular
context of bleomycin's action in vivo, an important offshoot of this work was to provide
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generic findings on DNA repair mechanisms that address radical mediated DNA damage
in vivo.
The remainder of the present chapter is devoted to background (along with a
literature review) on both the chemistry of bleomycin in vivo (Part B) and the
mechanisms of DNA repair (Part C). The rest of this dissertation is organized as follows.
Chapter II contains a detailed description of the materials and methodology used for this
study. Chapter III presents the results of the various experiments that were conducted.
Finally, Chapter IV summarizes the inferences that could be drawn from the experimental
data about bleomycin-induced damage and the mechanisms of DNA repair.
PART B: CHEMISTRY OF BLEOMYCIN
The cytotoxicity of bleomycin is thought to be due to its ability to damage DNA
(4). Three steps are required for this damage to occur. First, bleomycin must be
activated. Second, it must interact with the DNA. Third, the initial damage in DNA
leads to degradation. Of these three steps, steps one and three are fairly well understood.
However, the mechanism by which bleomycin interacts with DNA (step two) is still
unclear. In the following sections I shall present what is known about bleomycin, its
structure and the chemistry of its function.
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B L. Bleomycin Structure
The structure of bleomycin (BLM), as shown in Diagram 1, is divided up into six
functional domains (5):
1. the metal-complexing pyrimidine beta-hydroxymidazole moieties;
2. the DNA-binding bithiazole;
3. its terminal amine, which distinguishes various forms of bleomycin (A2 and
B2 being the major components of the clinically used formulation, which is
called "Bleoxane" (6);
4. the linker region, which attaches the bithiazole to the rest of the molecule and
determines the efficiency of double strand break;
5. the disaccharides important for uptake; and
6. the pyrimidinyl propionamide, which effects sequence specificity.
A variety of metal ions (i.e., Fe(II)/Fe(I)), Cu(I)/Cu(II), Co(III), Zn(II), Mn(II)
can form complexes with bleomycin to cause DNA damage (7; 8). However, only Fe(II)
and Cu(I)/Cu(II) are thought to be important for cytotoxicity (9; 10). Demetallo-
bleomycin is injected into patients' blood stream where it chelates Cu(II) in blood plasma
(9), and in this form enters cells. However, once in the cells, Cu(II) is displaced by Fe(II)
(10). It is in this iron bound form that bleomycin is thought to cause DNA degradation.
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B2. Bleomycin Activation
Activation of bleomycin, (BLM), requires oxygen and iron and is thought to occur
in vivo by either of two pathways (see Diagram 2). In the first, oxygen adds to
Fe(II)BLM, followed by the addition of one proton and one electron either from another
Fe(II)BLM complex (11), or from a thiol (12). Bleomycin can also be activated when
peroxide (HOOH) adds to Fe(III)BLM. Fe(III)BLM is a product once activated
bleomycin reacts with DNA (13) (see below).
Bleomycin ferric peroxide (HOO-Fe(III)BLM) or "activated bleomycin" is a
complex in which one coordination position of Fe(III) is occupied by the peroxide anion
(11). This intermediate, with a half-life of 2 min at 4 degrees Celsius is the last
detectable intermediate prior to DNA strand scission (11). At this point activated
bleomycin (or some transient intermediate form) acquires the ability to abstract hydrogen
atoms, which is key to DNA degradation.
It is unclear what exact form of bleomycin actually acts on the DNA. It is
possible that the peroxide itself initiates DNA cleavage. However, research by Stubbe et
al. suggests that the peroxide is actually cleaved via heterolysis of the 0-0 bond to a high
valence iron-oxo species such as O=Fe(V)BLM (8). It has also been argued that this
cleavage may be homolytic (resulting in O=Fe(IV)BLM), rather than heterolytic (14)
(Diagram 2). However, some evidence, including the lack of production of a peroxide
radical (15), has refuted this hypothesis.
Abstraction of a hydrogen returns activated bleomycin to the Fe(III) bleomycin
form. This species may be reactivated by addition of hydrogen peroxide (as mentioned
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above) or by reduction via some sulfhydryl-induction reduction reaction. Evidence
suggests that, in vivo, cytochromes (rather than glutathione) may act as this reducing
agent for bleomycin (16).
B3. Interaction of Bleomycin with DNA
It is generally accepted that bleomycin initiates DNA degradation by abstracting a
hydrogen atom from C-4' of the deoxyribose in DNA (to be described later). However, it
remains unclear how this activated bleomycin (HOO-Fe(III)BLM) actually interacts with
DNA. One reason for this uncertainty is that determining the structure of iron BLM-
DNA via NMR spectroscopy has proven to be very difficult, due in part to the instability
of the Fe(III)BLM (17). Much of the work in this field has thus been done on the
alternative metallo-BLM, specifically CoBLM. This compound is a less reactive analog
of activated BLM, cleaving DNA via the same C-4' hydrogen abstraction mechanism,
and with the same sequence context specificity (18; 19). Unlike Fe(III)BLM,
Co(III)BLM is exchange-inert and thus stable long enough for investigation by NMR. In
addition Co(III) is diamagnetic, which makes it especially amenable to NMR
spectroscopy (5).
Using data collected through NMR studies of HOO-CoBLM, Stubbe et al. have
proposed a well supported model for bleomycin structure and DNA interaction (5) (see
Diagram 3). According to this model, the bithiazole tail, inserting from the minor
groove, is intercalated between the stacked bases G14 and G15 of DNA. The pyrimidine
of bleomycin, important for sequence context specificity, is shown to form hydrogen
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bonds with G5 (specifically N3 and the amino group of the pyrimidine with a hydrogen
from the 2-amino group and N3 of G5, respectively). In their model, the terminal oxygen
of the hydrogen peroxide of HOO-CoBLM is shown to be located 2.5 angstroms from the
C-4' hydrogen, facilitating hydrogen atom abstraction form the sugar ring.
B4. DNA Degradation
When bleomycin abstracts a hydrogen atom from the C-4' of the deoxyribose, a
free radical is left in its place. At this point two different types of chemistry can occur,
resulting in two different types of DNA damage (Diagram 4).
If little oxygen is available (B of Diagram 4), the C-4' radical is believed to be
oxidized to a carbonium ion (21). This oxidation could be done by a putative
(OH)Fe(IV)=BLM generated by C-4' hydrogen abstraction into OF(III)(21). Reaction of
the carbonium ion with water results in a ring that is electron deficient. This sets the
system up for the release of the base, resulting in sugar ring opening. The final product is
a chemically modified apurinic/apyrimidinic site with a keytone at C-4' and an aldehyde
at C-i, (20; 21). The sugar of the AP site most likely exists in equilibrium between ring-
closed and ring-open forms.
A very different DNA degradation product will result if oxygen is abundant after
hydrogen abstraction. In this second pathway, the oxygen dependent pathway (A of
Diagram 4), an oxygen molecule adds to C-4' to form a peroxyl radical species, which
decomposes to give a strand break with 5'-phosphate and 3'-phosphoglycolate termini
with release of a base-propenal (22). The mechanism by which this chemistry occurs has
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been described by McGall et al. (Diagram 4) (23). Their work suggests that a rapid C-2'
hydrogen removal (step 4 in Diagram 4) induces cleavage of the O-C-l' bond, and thus
the opening of the Criegee-rearrangement sugar 4. This step is followed by a slow
release of the base propenal which can occur via two pathways (C and D of Diagram 4).
B5. Four Types of Bleomycin-induced DNA Damage
Based upon the discussion above, bleomycin-induced damage is a mixture of
strand breaks and abasic sites. These lesions have been shown to form in equal quantities
under physiological conditions (24). Cytotoxicity of bleomycin, however, is thought to
be due to double strand breaks (25). Between 10 and 33% (depending on sequence
context, see below) of bleomycin-induced DNA lesions are bi-stranded (26). These
lesions consist of either two chemically identical breaks in opposite strands, or an abasic
site with a closely opposed strand break (Two closely opposed abasic sites are never
formed; see Diagram 5) (26). The lesions in each strand are formed either directly
opposite each other, or with a 1-base stagger.
The choice of sites for initiating damage is based on a highly consistent hierarchy
of sequence-dependent selection rules (27). Single strand lesions occur specifically at a
5' GPy 3', where Py= C or T (the underline indicates cleavage site). Breaks occur at 5'-
GA-3' and 5' AT-3' with much lower frequency, occurring the least frequently at AT.
Following these sequence-dependent selection rules, the "hot spot" for double strand
breaks is at 5'-GTAC-3' cleavage (where the frequency of ds:ss lesions is 1:3 vs. the
normal 1:10). At this sequence, a highly favorable 5'-GT-3' cleavage site is provided in
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each strand. Other sites for bi-stranded damage always consist of a primary site that
conforms to the normal Gb sequence-specificity of bleomycin. The secondary site,
however, often occurs at sequences that would not be favorable for the formation of a
primary lesion (i.e., they do not necessarily follow the context rules described above)
(28). The abasic site is always formed at the secondary site, after a strand break event at
the first site. The discovery of this pattern of sequence context dependency suggests a
model by which one molecule of bleomycin could be generating these double strand
breaks. This model will be discussed in the following section.
B6. Mechanism of Double Strand Breaks
Theoretically speaking, there are two general mechanisms by which bleomycin
could cause double strand (ds) breaks. The first is that the double strand breaks are
formed from independent closely spaced single strand lesions (ss) in opposite strands.
This idea was ruled out in 1977 by Povirk et al. who demonstrated, using supercoiled
ColE1 and T2 DNA, that the ratio of ds to ss breaks was too high for double strand breaks
to be caused by random ss breaks (24). Thus, the second possibility, that one single
molecule of bleomycin causes breaks in opposite strands, was proposed.
Two observations support the hypothesis that bleomycin is in fact able to attack
the secondary site in the opposite strand without dissociating from the DNA. First, a
study by Absalon et al. of ss/ds-cleavage at a 5'-GTAC/5'-GTAC site revealed that the
ratio of the extent of ss to bi-stranded lesions is invariant over at least a 70-fold range in
concentration of Fe-BLM and extent in DNA degradation (29). The second rationale is
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that according to Burger et al, bi-stranded lesions are formed much faster than bleomycin
can be reactivated by sulfhydryls (30). Therefore, in order for one bleomycin molecule to
cause bi-stranded lesions without dissociating, it must be rapidly reactivated in situ
during the formation of the first strand break. The most accepted model for this
reactivation proposes that the original abstracting species of bleomycin is regenerated
through a direct reaction between the immediate bleomycin product of the hydrogen
abstraction and the 4'-peroxyl radical (31) (see Diagram 6).
One of the most important clues leading to models of the double strand cleavage
reaction was the discovery that the two sugars attacked are 15-18 angstroms apart (in B-
DNA) (29). This observation suggests that bleomycin must undergo substantial "re-
placement" between the first and second cleavage events. A model for this
rearrangement proposed by Vanderwall et al. (32) suggests that the bithiazole portion of
bleomycin remains intercalated between the bases, while the iron chelating complex
rotates 180 degrees across the minor grove (see Diagram 7), rotating around the (B-4')-
(B-C2) bond (see Diagram 1). These rearrangements place the hydrogen peroxide 3.4
angstroms from the 4' hydrogen of T15, which is the same hydrogen that is
experimentally found to be abstracted.
In order to position the metal binding domain in the minor groove of the second
cleavage site, the bithiazole ring system is rotated about 117 degrees around an axis
perpendicular to the rings while remaining coplanar to the DNA base pairs. These
rotations allow the relative orientation of the thiazole rings to the cleavage site to remain
the same for both positions. It also positions the bleomycin so that the same hydrogen-
bonding interactions occur between the metal binding domain and the G14 on the 5' side
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of the second cleavage site. This orientation is consistent with the high rate of double
strand cleavage at GTAC sequence, where the preferred GPy is provided at both the
initial and secondary cleavage sites.
PART C: BLEOMYCIN DAMAGE IN VIVO
Although much is known about the mechanism of action of bleomycin chemistry
in vitro, little is known about whether this same chemistry occurs in vivo. Bleomycin has
been shown to induce single and double strand breaks in cells (as well as in isolated
DNA) and under physiological conditions it seems that abasic sites and strand breaks
occur in a 1:1 ratio (24). According to Povirk, sequence-specificity studies done in vivo
suggest that these lesions result from drug-DNA interaction rather than, for example,
activation of apoptotic endonucleases (28; 33; 34). This is yet to be proven, however, and
the in vivo action of bleomycin as well as its mechanism of cytotoxicity are still, for the
most part, unknown.
One way to study what is occurring in vivo is to examine the relative sensitivities
of different repair or recombination deficient mutants to bleomycin. E. coli is often the
organism of choice for these types of studies, because its repair and recombination
systems are well studied, and mutants are readily available. Using this approach, Levin et
al. have demonstrated that bleomycin is indeed generating abasic sites in vivo (35).
Several other studies have demonstrated sensitivity in lexA and recA deficient E. coli (36;
37), (demonstrating that the SOS response is important for resistance to bleomycin). In
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addition, polymerase beta-based short patch pathways (base excision repair) and
aphidicolin-sensitive long patch pathways have been shown to be involved in the repair
of bleomycin-induced damage in human fibroblasts (38). Little, however, has been done
to examine the formation and repair of double strand breaks.
PART D: RECOMBINATIONAL REPAIR
The mechanisms by which double strand breaks are repaired is, in and of itself, an
important topic of investigation. In E. coli, a recombinational repair system is believed to
be responsible for the repair of double strand breaks (39). Recombinational repair, which
is also responsible for "tolerance" of DNA lesions encountered by the replication fork,
involves three steps (See Diagram 8): initiation, the Holliday junction formation, and
then resolution. Recognition of strand breaks and daughter strand gaps require separate
systems of enzymes. Once repair is initiated, however, the two repair systems converge.
Thus, the same enzymes are used for Holliday junction formation and resolution for both
double strand breaks and daughter strand gaps.
D1. Initiation
Recombinational repair is initiated by the recognition and binding of the DNA
damage, which is either a double strand break or a daughter strand gap (from the arrest of
the replication fork). In the case of double strand break, an enzyme complex of RecB and
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RecC (an ATPase, dsDNA exonuclease, DNA helicase, chi-specific endonuclease) binds
double strand breaks and then chews back blunt ends to form overhangs. The actions of
this complex are regulated by RecD, which when knocked out leaves cells recombination
proficient. However, the recBCD triple mutant has the same phenotype as recBC, which
demonstrates deficiency in double strand end repair (40).
RecF is also an initiator of recombinational repair; however, its role seems to be
limited (although this is still unclear) to the repair of daughter strand. RecF binds ss
DNA and brings RecA to the site of damage. It has been shown to bind RecO and RecR
to promote RecA binding to ss DNA. . coli mutants deficient in recF are deficient in
daughter strand gap repair (41).
D2. Holliday Junction Formation
Once the initiator binds, RecA is recruited to the site to initiate recombinational
repair. RecA, an ATPase, forms helical fliaments, and is a catalyst of homologous
pairing and strand exchange. E. coli mutants deficient in RecA are deficient in
recombination (42).
D3. Resolution of the Holliday Junction
Belonging to what are thought to be separate pathways, RuvABC and RecG are
both involved in the resolution of the Holliday junction (43; 44). RuvA has been shown
to bind Holliday junctions and, in doing so recruits RuvB. RuvB is an ATPase, and
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promotes branch migration, which is then resolved by RuvC, which cleaves the Holliday
junction. RecG shares similar functions as RuvABC, although it does not have the same
cleaving abilities as RuvC and it is thought to promote branch migration and
translocation of three strand junctions. Both recG and ruvAB mutants have slight
deficiencies in recombination, but the recGruvAB double mutant (which is identical to the
recGruvC mutant in phenotype) is severely deficient. This result suggests that the RecG
and RuvAB proteins have overlapping functions but are not fully interchangeable (45).
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Chapter II Materials and Methods
In order to determine whether the recombinational repair pathway is important for
repair of DNA damaged by bleomycin, mutants deficient in recombinational repair were
tested for sensitivity to bleomycin. Sensitivity of these mutants to bleomycin treatment
was examined under two conditions: conditions that promote cell division, and
conditions that arrest it. This Chapter describes the details on how these experiments
were carried out.
PART A: ESCHERICHIA COLI STRAINS USED
The recombinational repair E. coli mutants were used to probe the mechanism of
bleomycin genotoxicity. Six different mutants were examined; specifically the triple
mutants recBCD and ruvABC, double mutant recGruvC, and single mutants recF, recG,
ruvC. These strains were provided by Dr. Martin Marinus (University of Massachusetts
Medical School). The wild type strain, used as a control, is the common AB1157
originally created by DeWitt et al. (45). Details about the genotypes of each of these
strains can be found in Table 1.
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PARTB: BLEOMYCIN SOURCE AND USAGE
Bleomycin sulfate (Blenoxane), a mixture of bleomycin sulfate salts isolated from
Streptomyces verticillus, was purchased from Sigma. The copper content of this sample
was less than 0.1%. Half of the experiments were done with a culture tissue-tested batch
of bleomycin (denoted BLM*) (p. 1716, Sigma catalogue of 1998). The other half of the
experiments were done with a batch of bleomycin that was not culture tissue-tested
(p.190, Sigma catalogue of 1998). BLM was dissolved in 10 mM HEPES, KOH, pH 7.6,
at a concentration of 0.49 mM, and 0.24 mM for the second BLM* aliquot. The
concentration was determined by spectrophotometry, where E2 90= 14,000 M and the
molecular weight of BLM = 1440 g/mol (46).
PART C: GROWTH OF CELLS AND DRUG TREATMENT
C1. Treatment of Non-Dividing Cells:
The basic procedure used to probe mutant E. coli cells for sensitivity to bleomycin
was adapted from a procedure developed by Levin et al. (35). Cell cultures of various E.
coli strains were grown overnight at 37'C (spinning) in standard LB media
(Bactotryptone, Bactoyeast Extract, NaCl, pH 7.0) absent of any antibiotics. The
following day 10 pl of cells were diluted into 10 ml of fresh LB medium. These cells
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were then grown at 37"C (spinning) until cells were in exponential growth phase (OD600 =
0.3-0.6), which generally took about 3.5 hrs. At this point cells were transferred into
sterile 50 ml tubes and centrifuged for 15 minutes at 9000 rpm. The supernatant was then
poured off and the pellet re-suspended in 4 ml of M9 medium (Na2HPO 4, KH2PO4 NaCl
Na4Cl, CaCl2). The concentration of cells was then calculated, where ((OD600 x 6.7)-0.3)=
cells/ml. M9 was added until the concentration was 1.2 x 108 cells/ml. Aliquots of 450
pl of cells were treated with BLM at a final concentration of 8.3, 16.7, 33.4 and 50 pM
(where 50 pM = 72 ptg /ml). These cultures were then incubated at 37"C in a water bath
for two hours (Note that the volume of BLM/HEPES mixture added to cells was
approximately 50 ptl for each experiment). Reactions were then stopped by diluting the
cells in M9 medium, which was done by adding 10 pl of cells to 990 pl of M9. Cells,
diluted further into various concentrations, were then plated onto LB plates in order to
determine colony-forming units, a measurement of survival.
C2. Treatment of Dividing Cells
The same procedure as was used for treatment of non-dividing cells was used to
treat dividing cells, with the following alterations:
1. The cells were grown to early exponential phase, where OD=0.2-0.3 (thus, the
concentration was 1-1.7 x 108 cells);
2. Aliquots of 450pl of these cells were then treated directly (not spun down or placed in
M9);
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3. BLM* (a new batch, see above) at a final concentration of 0.8, 1.6, 3.2, 4.8 and 7 pM
(depending on the experiment) was added to these exponential phase, dividing cells.
Note that the second batch, with a stock concentration of 0.24 mM, was often diluted
by one fourth or one fifth in order to keep a volume of BLM*/HEPES mixture added
to cells at approximately 50 pl as above;
4. Cells were treated at 37'C for 1 hour, either in the water bath (as above) or in a shaker
(see below). The reaction was stopped by removing 100 pl of cells and adding this
portion to 900 pl of M9. Survival was measured as described above.
C3. Treatment of Shaking Dividing Cells
Some of the dividing cells (see treatment of dividing cells above) were placed in a
rotating 37"C incubator (rather than placed in the water bath) during treatment with
BLM*. For these cells, 900 pil were treated with 100 pl of the BLM*/HEPES mixture
with a finial BLM* concentration of 0.8, 1.6, 3.2 and 4.8 pM. This 1000 pl volume was
then placed in a 5 ml Falcon tube (with a culture tube cover so that air can pass through).
The tube was placed in a large culture tube with an eppendorf tube in the bottom (to hold
the falcon tube in place). This double tube setup was then placed in a rotator in an
incubator at 37"C for one hour. The cells were then treated as described in the previous
procedure.
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C4. How Sensitivity was Measured
Sensitivity of the various mutants was measured by comparing the fraction of
survival of each mutant to the fraction of survival of the wild type strain. The fraction of
survival was measured by dividing the number of cells that survived for each dose of
bleomycin by the number of the same type of cells that survived when no bleomycin was
added. The fraction of survival was then plotted as a function of bleomycin
concentration. The difference between fraction of survival of wild type and mutant at the
third dose of bleomycin treatment estimates sensitivity.
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Chapter III Results
This study of consists of four general experiments. In the first, the sensitivities of
various recombination/repair mutants were investigated in conditions that arrest cell
division (specifically, treatment in M9, a salt solution deficient in sugars and other
nutrients) (Part A). The effects of treating wild type E. coli cells under conditions that
promote cell division (specifically treatment in LB, a nutrient rich liquid broth, and
treatment in LB, shaking) were then examined (Part B). The last two experiments
examined how these two conditions, treatment in LB and shaking, affected the
sensitivities of the panel of recombination/repair deficient mutants (Part C and Part D).
PART A: SENSITIVITY OF NON-DIVIDING MUTANT CELLS TO
BLEOMYCIN:
The importance of RecB (which has the same phenotype as recBCD) in the repair
of bleomycin-induced damage has been demonstrated in a previous study (47). This
study shows that DNA reformation found in wild type E. coli cells is abolished in recB
mutants. Results in Figure 1 clearly support these earlier findings, demonstrating over
one log increased killing in the recBCD mutant as compared to wild type (at a dose of 30
VtM BLM). The recGruvC mutant was also shown to be as sensitive to bleomycin as
recBCD. Interestingly, neither recG, ruvABC nor ruvC deficiencies alone demonstrated
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sensitivity. The recF mutant also demonstrated no sensitivity to bleomycin. These
results have been summarized in Table 2.
PART B: DIVIDING CELLS DEMONSTRATE INCREASED SENSITIVITY
To BLEOMYCIN
In this first experiment, (Figure 1) cells were treated under conditions where they
were not dividing. Bleomycin is known to be more effective against dividing cells (48).
Therefore, this same experiment was conducted a second time, only under conditions
where the cells were allowed to divide during treatment with bleomycin. The results of
this experiment, presented in Figure 2, demonstrated that E. coli cells were much more
sensitive to bleomycin when they were dividing (approximately two and a half logs of
increased killing). However, shaking them while they were being treated (which should
increase division rate by providing oxygen) did not seem to increase sensitivity further
(Figure 2). Whether increasing oxygen increased cell division rate, however, was not
measured.
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PART C: SENSITIVITY OF DIVIDING MUTANT CELLS TO
BLEOMYCIN
Although a general increase in sensitivity of dividing cells to bleomycin was
predictable, a change in relative sensitivity of the various mutants was not (Figures 3 and
4). Figure 3 demonstrates that ruvABC, which was not sensitive to bleomycin in M9, was
extremely sensitive in LB. In fact, the sensitivity in LB was equal to that of recBCD and
recGruvC, the sensitivity of which seems to have increased to about 2.5 log of increased
killing as compared with the wild type strain. The ruvC and recG mutants also
demonstrated a slight increase in sensitivity having about a half a log of increased killing
as compared with the wild type strain (Figure 4). Interestingly, the sensitivity of ruvC
and recG were approximately equal in magnitude. The recF mutant, on the other hand,
remained insensitive to bleomycin when treated in M9 (Figure 4). The results have been
summarized in Table 2. It is important to note, however, that the data from Figure 4 were
obtained from a single experiment, and these results thus need to be confirmed.
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PART D: EFFECTS OF SHAKING ON SENSITIVITY OF DIVIDING
CELLS
If cell division is a factor in the differential sensitivities seen above, then shaking
the cells (which is known to increase E. coli dividing rate) during treatment with
bleomycin could affect the sensitivity of various mutants. Results in Figure 2
demonstrate that shaking also did not increase sensitivity of wild type. In Figures 5 and
6, we see that shaking did not seem to affect the relative sensitivity of the various
mutants. However, data from Figure 5 and 6 also need to be confirmed.
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Chapter IV Discussion
The results of this study, presented in Chapter III, examined two systems,
bleomycin function in vivo and recombinational repair, under two conditions, when cells
were dividing and when cells were not. This final Chapter discusses these results. Part A
examines the results from the first experiment, where the sensitivities of various
recombination deficient mutants to bleomycin were observed under conditions where
cells were not dividing (Chapter III, Al. and Figure 1). Conclusions about both
bleomycin damage and the mechanism of recombinational repair are inferred (Chapter IV
PartA). In the following section, how cell division during treatment with bleomycin
changes the function of these two systems (Part B-D) is discussed. Part G summarizes
general conclusions about the bleomycin-induced damage in vivo and the mechanism by
this damage is repaired. The final section (G2) proposes future experiments.
PART A: RECBCD AND RECGRUVC ARE IMPORTANT FOR REPAIR
Al. Bleomycin Induces Double Strand Breaks in Vivo
RecBCD specifically binds to double strand breaks. From the results in Figure 1
the recBCD mutant demonstrated significant sensitivity to bleomycin. This suggested
that bleomycin was indeed causing double strand breaks in vivo. This notion is supported
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by the fact that recGruvC mutants also demonstrated high sensitivity (Figure 1). At the
same time, sensitivity of recBCD and recGruvC indicates that recombinational repair was
important for repair of the lesions caused by bleomycin (Figure 1). Insensitivity of recF
suggested that it was the double strand break recombinational repair system (rather than
the daughter strand gap pathway) that was required for repair of bleomycin-induced
damage.
A2. Daughter Strand Gap Repair was Not Required
RecF is critical for the initiation of daughter strand gap repair, a mechanism that
allows the cell to "tolerate" or by-pass lesions during replication. The lack of sensitivity
of the recF mutants to bleomycin thus suggested that bleomycin was not creating lesions
that interrupt replication, and that the cell cannot repair (which would require bypass in
order to continue replicating). Recall, however, that in Figure 1, the cells were not
replicating. Daughter strand gap repair is required specifically during replication. Thus
in order to be sure that RecF (and thus daughter strand gap repair) was not involved in the
repair of bleomycin-induced damage, the sensitivity of recF mutants had to be tested
under cell division permissive conditions. Results in Figures 4 and 6 demonstrate that
recF remained insensitive when the cells were in LB (and therefore replicating). This
result further suggested that the daughter strand gap repair system is not important for
repair of bleomycin-induced damage.
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A3. RuvABC and RecG Have Redundant Functions
Both RecG and RuvABC are involved in resolution of the Holliday junction.
Although RecG and RuvABC are thought to resolve Holliday junctions through
independent pathways, they are also thought to have some overlapping functions (45).
Both the recG and ruvABC mutants have slight deficiencies in recombination, but the
recGruvAB double mutant (which is identical to the recGruvC mutant in phenotype) is
severely deficient (45).
Results from Figure 1 suggested that under the conditions where cells were not
dividing, the functions of recG and ruvABC were completely overlapping. This is shown
by the fact that the recGruvC double mutant was shown to be highly sensitive to
bleomycin, while none of the individual mutants, ruvABC, ruvC nor recG, were sensitive.
Perhaps under these conditions, the type of repair required was of a type that either RecG
or RuvABC can carry out. Under different conditions, however, where more damage or
different types of damage are induced, new functions of RecG and RuvABC are required
making them no longer interchangeable. This is what was seen in Figures 3 and 4 and
will be discussed in a later section.
A4. Sensitivity of recGruvC is Equal to That of recBCD
Two inferences can be made from the observation that, in Figure 1, recGruvC
exhibited the same level of sensitivity as recBCD. The first is that it supports the idea
that they are part of the same pathway. Knocking one out entirely eliminates the ability
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to repair double strand breaks (39). The second is that neither of these enzymes was
being used to repair other lesions created by bleomycin (such as daughter strand gap
repair). For if, for example, daughter strand gap repair was being engaged, then one
would have expected higher sensitivity of the recGruvC mutant than recBCD.
PART B: CELL DIVISION INCREASES SENSITIVITY To BLEOMYCIN
Bleomycin is known to be more effective on dividing cells than non-dividing cells
(thus providing a possible reason explaining why it is effective in cancer treatment).
Therefore it seemed important to see if the sensitivity of the wild type E. coli cells to
bleomycin would increase when the cells were treated in LB, where they would continue
to grow, versus M9, which, lacking nutrients necessary for division, slows or halts cell
growth. The results in Figure 2 demonstrated that, in fact, cells treated in LB, instead of
M9, were, at 5 pM BLM, 3 fold more sensitive than cells grown in M9.
There can be two general reasons for this increased sensitivity. The first is that
there was an increase in the number of lesions. The second is that each lesion was more
detrimental to the dividing cell than the non-diving cell.
B 1. Bleomycin Enters Cells More Efficiently?
There are, once again, several reasons why more lesions could be formed. It is
possible that under rapid growth conditions bleomycin was more effective at inducing
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damage. For example, when cells are dividing more iron or oxygen could be available
for bleomycin activation. A second possibility is that more bleomycin was getting into
the cells. Bleomycin is a large molecule and the exact mechanism by which it enters cells
is unknown, although some evidence suggests that it is actively transported into the cells
(49). Evidence that supports the idea that it is actively transported is the fact that after
several hours of treatment, intracellular concentrations of bleomycin remain lower than
the extra-cellular concentrations (50). Perhaps, during cell division, bleomycin is able to
enter cells more easily. This is another possible explanation for increased toxicity when
cells are treated with BLM in LB.
B2. Each Lesion is More Detrimental In Dividing Cells
The second general cause for increase sensitivity could be that each lesion was
more detrimental to the cell when the cell was dividing then when it was not. When cells
are dividing there is less time to repair damage. In addition, the process of attempting to
replicate this damaged or "intercalated" DNA could lead to damage or cell death, which
would not occur were the cells not being replicated. In order to investigate this
possibility further, I decided to alter another variable that should increase cell replication,
namely the oxygen level.
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B3. Increasing Oxygen Has No Effect on Sensitivity to BLM
Cell growth rate is not only dependent on available sugar and other nutrients but
on oxygen as well. Oxygen acts as the terminal electron acceptor in respiration. If
media, in which E. coli cells are growing, are not supplemented with oxygen during
growth (i.e., by shaking), oxygen levels are depleted with in 15 minutes (51). Thus, in
order to enhance cell growth further, cells, incubated in LB, were shaken during treatment
(rather than being placed in a water bath). Although the addition of sugar enhanced
sensitivity to bleomycin drastically, shaking, as seen in Figure 2, had no obvious effect.
There are two ways to explain the fact that shaking had no effect. One
explanation could be that the method of shaking was not effective in increasing oxygen
levels significantly to alter cell division. However, this method is the standard method of
increasing oxygen in LB during E. coli growth. Another method by which lesions could
have been increased is the following. As stated earlier bleomycin is believed to enter
cells via some type of transport mechanism. It is known that the sugar moieties on
bleomycin are crucial for this form of transport (52). One possibility is that bleomycin is
taken up as a "modified" sugar so that when the cells are in LB, channels important for
transporting sugar into the cell are opened, allowing bleomycin to enter the cell, along
with the sugars, at a much higher rate. This theory could be tested easily by fluorescent
or radio labeling of bleomycin and examining rate of uptake into the cells in different
media.
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PART C: TREATMENT IN DIVIDING CELLS INDUCES NEW REPAIR
PATHWAYS
Increased sensitivity of dividing cells to bleomycin may be due to increased
number of lesions. In this case, all of mutants sensitive to bleomycin in non-dividing
cells should demonstrate increased sensitivity. Likewise, the mutants insensitive in non-
dividing cells should remain insensitive. However, increased sensitivity may be due to
alterations in the types of damage that bleomycin is inducing. In this case, the specific
mutants that are sensitive to bleomycin may change. In order to determine if treatment of
dividing cells (versus non-dividing) actually changes the types of mutations induced by
bleomycin, the various recombination/repair mutants were treated with bleomycin in LB
and examined for sensitivity.
C 1. A New Function for RuvAB
In non-dividing conditions the phenotypes of recG, ruvABC and ruvC were equal
(namely no sensitivity to bleomycin). The high sensitivity of recGruvC mutants
suggested that either recG or the ruvABC complex was needed, but that functionally one
could replace the other. The fact that RuvA, RuvB and RuvC work together to resolve
Holliday junctions would suggest the ruvC and ruvABC mutants are equivalent. This
hypothesis was supported by the fact that both the ruvC and ruvABC strains were
insensitive to bleomycin. From this result one could conclude that, functionally, the recG
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is equivalent to the ruvAB mutant, which is equivalent to ruvC (see Chart 2). However,
the results in Figures 3 and 4 suggest that ruvAB has a function independent of recG and
ruvC. This function is essential for repair of damage done by bleomycin only under
conditions where cells are dividing.
C2. RuvAB is Essential and Independent of RuvC
When dividing cells were treated with bleomycin, the sensitivity of the ruvABC
strain went from zero to a sensitivity exactly equal to that of recGruvC and recBCD (two
and a half logs of killing as compared with wild type). This observation suggested that a
function of ruvABC, which was not essential in non-dividing cells (Figure 1), became
essential to repairing lesions induced by bleomycin when dividing cells were treated
(Figure 3). Although the sensitivities of recG and ruvC (which were, interestingly
enough, equal) also increased, the sensitivities of these two mutants was still less than
that of ruvABC, recGruvC and recBCD by almost two logs. Thus in these conditions
ruvC and ruvABC no longer shared the same phenotype. From these results, one can
infer that it is RuvAB (rather than RuvABC) that acquired this new function important
for repair of bleomycin-induced damage. Sensitivity of the ruvAB mutant to bleomycin
should be examined under these conditions to confirm this result.
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C3. RuvABC and RecG are Not Exchangeable
Overall, these data suggested that under these conditions both of the resolution
pathways in recombinational repair (recG and ruvABC) were now needed to protect the
cell against damage induced by bleomycin. Whether this was due to an increase in the
number of lesions or an alteration in the types of damage caused by each molecule of
bleomycin is unclear. The fact that sensitivity of recGruvC and recBCD mutants
increases in dividing cells suggested that the general amount of damage repaired by
double strand break recombinational repair increases. The fact that recF mutants
remained insensitive to bleomycin suggested that at least damage requiring daughter
strand gap repair was not invoked.
PART D: SHAKING CELLS HAS NO EFFECT ON SENSITIVITY TO
BLEOMYCIN
The ability of bleomycin to cause double strand breaks was dependent on the
availability of oxygen. Thus shaking the cells, which increases oxygen levels in the
medium could theoretically increase the ability of bleomycin to cause double strand
breaks. The lack of increased sensitivity or alteration in sensitivity therefore suggested
two points. The first is that the oxygen availability is not altered (i.e., all of the increased
oxygen was used by the E. coli cell for division). The second possibility was that
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increasing oxygen in this manner did not alter the chemistry of bleomycin and its
interaction with DNA. The fact that shaking had no effect on the pattern of sensitivity of
the various recombination/repair mutants (Figures 5 and 6) suggested that in fact, shaking
did not alter the types of damage induced by bleomycin. Data in Figures 5 and 6 have
only been tested a few times, however and need to be re-tested in order to confirm this
conclusion.
PART E: BLEOMYCIN INDUCES SENSITIVITY OF E. COLI TO HEPES
BUFFER: LIPID PEROXIATION?
One of the side effects of bleomycin treatment is alveolar cell damage and
subsequently pulmonary inflammation (53). This is not thought to be caused by damage
of DNA in lung alveolar cells, but rather by damage of the lipid membranes of the cells.
Bleomycin is known to be able to induce lipid peroxidation (54). During this study, this
"other" function of bleomycin seems to have been revealed.
During one experiment instead of diluting cells in M9 (as usual), they were
accidentally diluted in HEPES. Although all of the zero bleomycin added cells grew
normally (counting 2-5x108 cells) (data not shown), all of the cells treated with
bleomycin, from 0.8-4.8 pM, were 100% killed. This result suggested that bleomycin
somehow made the cells vulnerable to this new environment. Considering bleomycin's
known ability to induce lipid peroxidation (54), it was possible that in this experiment
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bleomycin actually created holes in the cell walls. This "poration" then enabled HEPES,
which is N-2-hydroxyl ethyl piperazine-N'-2-ethane sulfonic acid in salt and buffer, to
flow into or suck water out of the cell. This lipid peroxidation activity of bleomycin
should be investigated further as it could significantly affect its mechanism of
cytotoxicity in vivo.
PART F: CONCLUDING THOUGHTS
Fl. Conclusions About the Genotoxicity of Bleomycin In Vivo:
From this study, several inferences can be made about the genotoxicity of
bleomycin. Results from this study indicated that bleomycin induced double strand
breaks in vivo. At the same time, bleomycin did not seem to create lesions that block
replication and required daughter strand gap repair.
In this study, bleomycin was shown to be more effective against dividing cells.
Increased sensitivity of dividing cells to bleomycin could be due to increased uptake of
bleomycin by dividing cells. However, alterations in the sensitivity of the various
mutants suggested that new types of repair systems were required when dividing cells
were treated. This result suggested that, in dividing cells, new types of damage were
induced. Perhaps the same lesions created in non-dividing cells were more detrimental to
the cells when they were replicating their DNA. However, a large increase in DNA
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damage could also have been overwhelming the repair system used in non-dividing cells,
requiring the involvement of a new set of enzymes in dividing cells.
The fact that shaking, which is known to increase cell division, had no effect on
the sensitivity of cells to bleomycin suggested that it is not cell division that caused an
increase in sensitivity. This suggests the theory that sugar may be important for uptake of
bleomycin. However, this is all speculative. Why bleomycin is more effective in
dividing cells needs to be investigated further.
F2. Conclusions On The Mechanism of Recombinational Repair
From this study new insights are also gained about the roles of the various
recombinational repair enzymes in the repair of bleomycin-induced damage. RuvABC
and RecG seemed to be interchangeable for the types of damage induced when treated in
M9. In addition, under these conditions, ruvABC and ruvC seem to be operationally the
same mutant. The equal sensitivity of the recBCD and recGruvC mutants confirmed the
model proposed by Cox that these two enzymes function as part of the same pathway
(RecBCB functioning upstream of RecG and RuvABC) (39). However, when dividing
cells were treated, RuvABC took on a role that was essential and seemingly independent
of both RuvC and RuvG. This result suggested that the function of these enzymes may
be multi-modal.
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F3. Clinical Significance of Results
The results of my work are consistent with experience of usage of bleomycin in
the clinical world. Bleomycin is generally used clinically in combination with other
chemotherapeutic drugs such as cisplatin. Damage induced by cisplatin is also addressed
by recombinational pathways, to an even greater extent than bleomycin (55). If cells
were treated by both agents, their recombination system would be severely taxed and
possibly overwhelmed, especially in rapidly growing cells where bleomycin damage
seemed to affect at least two recombination pathways at once (recG and ruvABC). A
better understanding of how these drugs target dividing cells and affect the repair system
will enable the design of more effective drugs for combating cancer.
PART G: FUTURE EXPERIMENTS
The results of this study lead to many questions that should be further
investigated. Experiments investigating the genotoxicity of bleomycin will be described
first. Then, in the following section, experiments examining the mechanism of
recombinational repair are proposed.
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G1. Testing The Mechanism of Bleomycin Genotoxicity
From this study it is clear that bleomycin caused double strand breaks in vivo.
Studies by Levin and Demple have also demonstrated that bleomycin induces abasic sites
in vivo, requiring repair by endonuclease IV (35). At this point it would be very
interesting to determine, in vivo, the relative importance of these two types of damages.
One way to do this would be to examine an endonuclease IV deficient, recBC deficient
triple mutant, for example. The results of this experiment would also indicate whether
abasic sites lead to double strand breaks.
The toxicity of bleomycin was much higher in dividing cells. One possibility is
that in dividing cells bleomycin was actually causing a higher number of double strand
breaks. One way to examine if levels of damage were actually increased DNA would be
to examine the sensitivity of recA, lexA, recN deficient mutants to bleomycin under
dividing and non-dividing conditions. These three genes are important for the SOS
response and thus would indicate whether the general SOS response was increased when
cells were treated in M9, LB or LB-shaking. The levels of DNA damage should also be
examined directly to see if one actually gets increased damage in dividing cells.
It is possible that bleomycin enters dividing cells more efficiently than non-
dividing cells. In order to test this hypothesis, fluorescence labeling could be used to
visualize transport of bleomycin into dividing versus non-dividing cells. The effects of
sugar on transport of bleomycin into cells could also be tested in this manner.
Our results suggested that shaking, and thus increasing oxygen, has no effect on
the genotoxicity of bleomycin. However, it is known from in vitro studies of bleomycin
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(see Chapter 1, B4) that availability of oxygen affects the types of DNA damage induced
by bleomycin. In order to examine further the effects of oxygen on the genotoxicity of
bleomycin, oxygen could be bubbled into M9 medium during treatment of cells with
bleomycin. Under these conditions, sensitivity of the various recombinational repair
mutants should then be examined. The results of this experiment would indicate the
importance of oxygen to bleomycin's cytotoxicity. This would be helpful for
understanding its function as a chemotherapeutic agent, as cancer cells tend to suffer from
hypoxia.
G2. Testing the Mechanism of Recombinational Repair
Results from this study suggest that RuvAB may have a role that is independent
of ruvC. This role was observed in bleomycin-treated dividing cells. When non-dividing
cells were treated however, the ruvABC and ruvC mutants had the same phenotype. In
order to confirm this suspicion, the sensitivity of the ruvAB mutants (versus the ruvABC
mutants) should be examined under both cell division permissive and non-permissive
conditions. For this same reason the ruvABrecG mutant, which has been claimed to have
the same phenotype as ruvCrecG (45), should also be tested for sensitivity to bleomycin
in both cell division permissive and non-permissive conditions.
These studies will improve our understanding of how E. coli repair double strand
breaks. Although the exact mechanism of repair may be different in humans,
understanding how these repair machines work in . coli can give new insights as to how
human cells repair double strand breaks.
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Diagram 1: Structure of Bleomycin and Its Six Domains: the metal-complexing beta-hydroxymidazole; DNA binding bithiazole;
its terminal amine which distinguishes various forms of BLM; the linker region which determines efficiency of double strand breaks;
disaccharides important for uptake and, the pyrimidinyl propinonamide, which effects sequence specificity. (Diagram was
adapted from Wueta/. (1996) J. Am. Chem, Soc., 118:1268-1280)
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Diagram 2: Bleomycin Activation Pathways. Labels
(Diagram was adapted from Dedon, R, Goldberg,
1 and 2 indicate the two main pathways for activation of Bleomycin.
I., J. Am. Chem.Soc. (1992) 5: 311-331)
Fe(IU)BLM
Diagram 3: Structure of Co-BLM A2, colored green (atoms colored by element C =green, O=red,
N=blue, S=yellow) bound to DNA (purple, C6-H4' = white), Damaged strand is in the foreground,
running 5' to 3'from the upper right to the lower left corner. The doffed lines indicate the H-bond
interactions between the pyrimidinyl propionamide moiely of CoBLM and the G5 of the DNA.
Also indicated is the proximity of the distal oxygen of the hydroperoxide ligand to the C6-H4' (2.5 angstroms).
(Figure was taken from Wu, W, Vanderwall, D., Turner, C., Kozarich, J., Stubbe, J., J. Am. Chem. Soc.
(1996), 118, 1281-1294)
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Diagram 4: Proposed Mechanism of Bleomycin-induced DNA Degradation. Bleomycin initiates degradation via
hydrogen atom abstraction from the 4' carbon of the deoxyribose. This initial, hydrogen abstracted, sugar and the final
products of degradation are boxed. (Diagram was adapted from Dedon, P, Goldberg, I., J. Am. Soc. (1992)5,311-331)
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Diagram 5: Four Types of Damage Induced by Bleomycin. Bleomycin can create
abasic sites (1), single strand breaks (2), double strand breaks (3) and single strand breaks
opposing abasic sites (4). (Diagram was adapted from Povirk, L., Mutation Research
(1996) 71-89)
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Diagram 6: Proposed Mechanims of Bleomycin Reactivation Enabling Double
Stranded Lesions. (Diagram was adapted from Absalon, M.J. Kozarich,J. and Stubbe,
J., Biochemistry (1995) 34, 2076-2086)
Diagram 7: Model of Bleomycin Flipping During Double Strand Cleavage. The
translocation of the metal-binding domain of HOO-CoBLM from T5 (dashed lines) to T15
(solid lines) occurs by a rotation around the (B-C4')-(B-C2) bond and the repositioning of
the bithiazole. The 4' hydrogens at T5 and T15 are circled and the 04' of DNA is shown as
a gray sphere. (Diagram was adapted from Valderwall et al. Chem. Biol., (1997) 4: 373-
387)
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Diagram 8: The Two Pathways of Recombination/Repair. Although daughter strand
gap (on the left) and double strand break (right) are initiated with different enzymes
(RecFOR vs RecBCD), they share the same enzymes for Holliday junction formation
(RecA) and resolution (RuvABC or RecG). The diagram was adapted from Michel Cox
(Cox, M. Proc. Nati. Acad. Sci. USA (1997) 94 11764-1176).
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Table 1: Recombination/Repair Mutants Used for Examining the Mechanism of
Bleomycin Genotoxicity
Repair/Recombi
nation Status
WT
Strains Genotype
ABI157 F-thr-ara-141euB6 DE(gpt-proA)62 lacYl tsx-33 glnV44(AS) galK2(Oc)
rfbD 1mg 1-5 1rpoS39g(Am)rspL3 1 (Str) KdgK5 1xylA5mtl- 1 argE3(Oc)thi- 1
recBCD
recF
ruvABC
ruvC
recG
recGruvC
KM21
JCN239
AM547
CS85
N3793
N3398
ArecC ph recBrecD::KanR
recF143
ruvA60::TnlO ruvB52 ruvC53
ruvC53
ruvC53 recG258
ruvC53 recG258
Wild type strain was isolated by DeWitt and Adelbeg EA., (1962) Genetics 47,
pg. 577. All of the mutants strains were kindly provided by M. Marinus, Univeristy of
Massachusetts Medical School, Worchester MA.
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Table 2: Relative Sensitivities of Wild Type and Recombination Mutants to
Bleomycin: A Qualitative Summary of the Results in Figures 1, 3 and 4.
Relative
Sensitivity Non- Dividing Cells Dividing Cells
The relative sensitivity of each strain as compared with the wild type strain was
estimated at doses of bleomycin of: between 20 to 50 pM for non-dividing cells and 2 to
5 pM for dividing cells. A relative sensitivity of "0" means that the strains were as
sensitivite to bleomycin as wild type. The + means that strains were more sensitive to
bleomycin than wild type by about half a log. Each additional + represents an additional
half a log of increased sensitivity as compared to sensitivity of the wild type strain.
63
0 WT, recF, recG, ruvAB, ruvC WT, recF
+ r|C, recG
++ recBCD, recGru*t
++++ ruvABC, recBCD, recGru&C
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FIGURE]: SENSITIVITY OF MUTANTS TO BLM IN NON-DIVIDING CONDITIONS. Cultures of E. coli strains were grown to the exponential
phase as described in the text. These cells were then centrifuged and the pellets re-suspended in M9 to a final concentration
of 1.2x 108 cell/ml. These cells were then treated with bleomycin at concentrations of 8.3, 16.7, 33.4 and 50 uM (where 50 uM
= 72 ug/ml) for 2 hrs. For each point, an aliquot of cells was diluted into M9 and plated in order to determine colony-forming
units (46). Each point represents the average of between three to six independent experiments. The error bars represent
standard error of the mean.
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FIGURE 2: SENSITIVITY OF WILD TYPE E. COLI TO BLM IN NON-DIVIDING VS. DIVIDING CONDITIONS. Cultures of E. coli strains
AB] 157 were grown to the exponential phase as described in the text, These cells were then treated with
bleomycin at concentrations of 1.2, 2.3, 4.7 and 7 uM (where 7uM = 11 ug/ml), for 2 hrs when treated in M9 or ] hr
when treated in LB. When the cells were shaken, concentrations of 0.8, 1.6, 3.2 or 4.8 uM of bleomycin were used
(1 hr incubation). For each point, an aliquot of cells was diluted into M9 and plated in order to determine colony-
forming units (46). Data are from one experiment but the same results have been observed in other experiments
where wild type was used as a control (see other figures).
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FIGURE 3: SENSITIVITY OF RECGRUVC, RECBCD, AND RUVABC MUTANTS TO BLM IN DIVIDING CONDITIONS. Cultures of E. coli
strains were grown to the exponential phase as described in the text. These cells were then treated with BLM at
concentrations of 1.2, 2.3, 4.7 and 7 uM (where 7 uM = 11 ug/ml) for 1 hr. For each point, an aliquot of cells was diluted
into M9 and plated in order to determine colony-forming units (46). Each point represents the average of between
three to six independent experiments. The error bars represent standard error of the mean.
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FIGURE 4: SENSITIVITY OF RECG, RUVC, RECF MUTANTS TO BLM IN DIVIDING CONDITIONS. Sensitivities of recGruvC and ruvABC
mutants were plotted for comparison. Cultures of E. coi strains were grown to the exponential phase as described in the
text. These cells were then treated with BLM at concentrations of 1.2, 2.3, 4.7 and 7 uM (where 7uM = 1] ug/ml) for 1 hr. For
each point, an aliquot of cells was diluted into M9 and plated in order to determine colony-forming units (46). Data are
from one experiment and needto be duplicated.
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FIGURE 5: SENSITIVIY OF RECGRUVC, RECBCD AND RUVABC MUTANTS TO BLM IN DIVIDING AND SHAKING CONDITIONS. Cultures of E. coli
strains were grown to the exponential phase as described in the text, These cells were then treated with bleomycin at
concentrations of 0.8, 1.6, 3.2, and 4.8 uM (where 4.8 uM = 6.9 ug /ml) for 1 hr while being shaken. For each point, an aliquot of
cells was diluted into M9 and plated in order to determine colony-forming units (46). Data are from one experiment and thus
needto be duplicated.
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FIGURE 6: SENSITIVIlY OF RECG, RUVC AND RECF TO BLM IN DIVIDING AND SHAKING CONDITIONS. Cultures of E. coli strains were grown
to the exponential phase as described in the text. These cells were then treated with bleomycin at concentrations of 0.8, 1.6,
3.2 and 4.8 uM (where 4.8 uM = 6.9 ug/ml) for 1 hr while being shaken. For each point, an aliquot of cells was diluted into M9
and plated in order to determine colony-forming units (46). Data are from one experiment but have been duplicated in two
experiments. Additional experiments should be done to confirm these results.
